Clinical and Epidemiological Characterization of patients with Systemic Lupus Erythematosus
Keywords:
Lupus Erythematosus, Systemic, Autoimmune, Autoantibodies, AutoantigensAbstract
Introduction: Systemic Lupus Erythematosus is an autoimmune, chronic and unknown disease, with many clinical and multisystem manifestations, as an answer to the production of autoantibodies against autoantigens. Objective: To characterize the patients with systemic lupus erythematosus from the clinical and epidemiological point of view. Method: A descriptive investigation of 112 patients with diagnosis of systemic lupus erythematosus assisted at Arnaldo Milián Castro University Teaching Hospital from January 2006 to December 2015. Results: Patients between 30 and 39 years of age were the most representative with a highest incidence in white patients and the female sex. Systemic Lupus Erythematosus prevailed as family antecedent. Facial erythema, arthritis and photosensitivity remained as frequent starting manifestations. Infections were the main cause of hospitalization. Prednisone and Azathioprine were the most used medication. Conclusions: Systemic lupus erythematosus appears with a higher frequency in the female sex, in young stages of live, having a high predisposition to get infection.
Downloads
References
Gutiérrez Rivera MC. Terapéutica del Lupus eritematoso sistémico. [Internet]. 2012 Dic [citado 20 Feb 2016]. Disponible en: http://es.scribd.com/doc/18467669/Lupus-Eritematoso-Sistemico
Izquierdo JA, Martínez NC, Ochaita PL. Características epidemiológicas de los pacientes con lupus eritematoso cutáneo. Actas Dermo-Sifiliográficas. 2014;105(1): 69-73.
Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, Galindo-Izquierdo M, Loza E, de Yebenes MJG, Pego-Reigosa JM. Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. Reumatología Clínica. 2014;10(1):17-24.
Robert G. Plantel Liberty Health the Hosp. Mount Sinai Jersey City, NJ. New York College of Medicine, NY. [Internet]. 2012 [citado 7 Ene 2016]. Disponible en: http://www.alua.org.ar/ques.htm
Bastida Aguilar L. Jornada LES [Internet]. 2012 Abr [citado 7 Dic 2016]. Disponible en: http://www.jornada.unam.mx/2012/04/05/ls-lacontra.html
Dubuc CAE, Ecenarro MU, Villalba CM, Cáceres VA, Rubio IH, Otano JB. Síndrome hemofagocítico como manifestación clínica inicial del lupus eritematoso sistémico. Reumatología Clínica. 2014;10(5):321-4.
Martínez Larrarte JP, Padilla-Docal B, Dorta-Contreras AJ, Narváez P, Alberto L, Fernández Zamora O. Estudio neuroinmunológico en un paciente con manifestaciones neuropsiquiátricas en el lupus eritematoso sistémico. Revista Cubana de Reumatología. 2014;16:385-90.
Pretel M, Marquès L, España A. Lupus eritematoso inducido por fármacos. Actas Dermo-Sifiliográficas. 2014;105(1):18-30.
Lazaro E, Richez C, Seneschal J. Lupus eritematoso sistémico. EMC-Aparato Locomotor. 2015:48(1):1-17.
Kokuina E. Autoanticuerpos como biomarcadores de actividad de la enfermedad del lupus eritematoso sistémico. Revista Cubana de Medicina. 2014;53(2):201-23.
Maury D MS, Escobar MR, Naranjo LAG, García ALV, Vahos CHM, Duque GMV. Ciento quince pacientes con lupus eritematoso sistémico: características clínicas e inmunológicas. Revista Colombiana de Reumatologia. 2014;21(4):183-92.
Wang J, Kay AB, Fletcher J, Formica MK, McAlindon TE. Is lipstick associated with the development of systemic lupus erythematosus (SLE)?. Clin Rheumatol. 2008; 29(9):1183-97.
Kids Speak Out about Lupus. Lupus Foundation of America [Internet]. 2013 [citado 7 Feb 2014]. Disponible en: http://www. Lupus. Org/ webmodules/webarticlesnet/ templates/ new-about. Aspx?
Villa Blanco I, Calvo Alén J. Lupus Eritematoso Sistémico. En: Sociedad Española de Reumatología. Manual SER de las Enfermedades Reumáticas. 6ta ed. España: Elsevier; 2014. p. 335-347.
Anselm M, Sen Hee T. Environmental factors, toxicants and Systemic Lupus Erythematosus. Int J Mol Sci. 2014;15:16043-16056 [Internet]. 2014 [18 Agos 2016]. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200809/pdf/ijms-15-16043.pdf
Miranda-Hernández D, Cruz-Reyes C, Angeles U, Jara LJ, Saavedra MA. Predictores de respuesta al tratamiento en pacientes con nefritis lúpica. Reumatología Clínica. 2014;10(3):164-9.
Tetikkurt C, Yuruyen M, Tetikkurt S, Bayar N, Ozdemir I. Propylthiouracil-induced lupus-like or vasculitis syndrome. Multidiscip Respir Med [Internet]. 2012 [citado 18 Agos 2016];7(1):14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/22958435
Guibert Toledano ZM, Reyes Llerena Gil A, Hernández Martínez A, Torres Carballeira R. Medición de actividad lupidica en pacientes portadores de Lupus Eritematoso Sistémico (LES). Rev Cubana Reumatol [Internet]. 2000 [citado 18 Agos 2016];2(1):4-11. Disponible en: https://dialnet.unirioja.es/descarga/articulo/4940588.pdf
Siachoque-Montañez H, Ibáñez-Pinilla M, Iglesias-Gamarra A. Defectos en la expresión de cadena zeta en un grupo de pacientes con lupus, escleroderma y artritis de inicio tardío, Colombia 2014. Rev Cienc Salud. 2014; 12(3): 303-18.
Estévez del Toro M, Chico Capote A, Echavarría R, Jiménez Paneque R, Kokuina E. Daño en pacientes cubanos con lupus eritematoso sistémico. Relación con características de la enfermedad. Reumatol Clin [Internet]. 2010 [citado 7 Sept 2016];6(1):11-15. Disponible en: http://www.reumatologiaclinica.org/es/pdf/S1699258X09001569/S300/
Singh N, Traisak P, Martin KA, Kaplan MJ, Cohen PL, Denny MF. Genomic alterations in abnormal neutrophils isolated from adult patients with systemic lupus erythematosus. Arthritis Res Ther [Internet]. 2014 [citado 18 Agos 2016];16:R165. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107853/pdf/10.1177-0961203313497115.pdf
Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther [Internet]. 2011 Mar 17 [15 Jul 2016]; 13(2):207. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132009/pdf/ar3251.pdf
Guibert Toledano ZM. Actividad lúpica y daño acumulado en una cohorte de pacientes cubanos con lupus eritematoso sistémico (LES) [tesis]. La Habana: Hospital Clínico Quirúrgico 10 de Octubre; 2009 [Internet]. [citado 7 Feb 2014]. Disponible en: http://tesis.repo.sld.cu/126/1/Zoila_Marlene_Guibertoledano.pdf
Alarcón GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Infect Dis Clin North Am. 2006; 20:849-75.
Muñoz-Grajales C, Pinto Peñaranda LF, Velásquez Franco CJ, Márquez Hernández JD, Restrepo Escobar M. Complicaciones infecciosas en lupus eritematoso sistémico. Rev Colomb Reumatol. 2013;20(3):141-147.
Sifuentes Giraldo WA, García Villanueva MJ, Boteanu AL, Iglesias AL, Zea Mendoza AC. Nuevas dianas terapéuticas en el lupus sistémico. Reumatol Clin. 2012;8(5):263-269.
Villa-Blanco I, Calvo-Alén J. Utilizing registries in systemic lupus erythematosus clinical research. Expert Rev Clin Immunol. 2012; 8:353-60.
Iriya SM, Capelozzi VL, Calich I, Martins MA, Lichtenstein A. Causes of death in patients with systemic lupus erythematosus in São Paulo, Brazil: a study of 113 autopsies. Arch Intern Med. 2001;161:1557.
Aranow C, Diamond B, Mackay M. Systemic lupus erythematosus. Rich R. Clinical immunology principles and practice. 3rd ed. Philadelphia: Mosby; 2008. p. 749-76.
Jordan N, Lutalo PM, D’Cruz DP. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Medicine [Internet]. 2013 [5 Agos 2016];11(1):120. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667088/pdf/1741-7015-11-120.pdf
Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus – report of 17 cases and review of the literature. Lupus [Internet]. 2013 [citado 5 Agos 2016];22(9):932-939. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107853/pdf/10.1177-0961203313497115.pdf
Calvo-Alén J, Silva-Fernández L, Úcar-Angulo E, Pego-Reigosa JM, Olivée A, Martínez-Fernández C, Gómez-Reino JJ, et al. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. Reumatol Clín[Internet]. 2013 [citado 5 Agos 2016];9(5):281-296 . Disponible en: http://www.reumatologiaclinica.org/es/consenso-sociedad-espanola-reumatologia-sobre/articulo/S1699258X13000922/
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
